StockStory.org on MSN
DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...
Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom A warning ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results